Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate, galeterone, is a multi-targeted, oral small molecule being developed for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. The company was founded in 2004 and is based in ...
255 State Street
Boston, MA 02109
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $608.5K
Chief Financial Officer
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & Development
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.
Tokai Pharmaceuticals, Inc. Key Developments
Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 12 15
Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $8,982,000 compared with $5,885,000 for the same period a year ago. Net loss was $8,957,000 or $0.40 per basic and diluted share compared with $5,851,000 or $11.68 per basic and diluted share for the same period a year ago.
For the six months, the company reported loss from operations of $22,282,000 compared with $10,777,000 for the same period a year ago. Net loss was $22,217,000 or $0.99 per basic and diluted share compared with $10,698,000 or $21.48 per basic and diluted share for the same period a year ago.
Tokai Pharmaceuticals, Inc. Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer
Jun 24 15
Tokai Pharmaceuticals, Inc. announced the initiation of ARMOR3-SV, the company's pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. The company also announced that the components of the AR-V7 clinical trial assay have been finalized by its collaborator, Qiagen, and that global deployment of the assay is now underway. ARMOR3-SV will compare galeterone to Xtandi® (enzalutamide) in 148 mCRPC treatment-naïve patients whose prostate tumors express the AR-V7 splice variant. These truncated ARs are missing the C-terminal end of the AR that contains the ligand-binding domain, which is known as C-terminal loss. AR-V7 is the most common form of C-terminal loss. The pivotal trial will employ a precision medicine approach for selection of patients with the AR-V7 splice variant by using an AR-V7 clinical trial assay successfully optimized for global use by Qiagen. The primary endpoint of ARMOR3-SV is radiographic progression-free survival assessed by blinded independent central review. The design of ARMOR3-SV is aligned with feedback obtained from the U.S. Food and Drug Administration and the European Medicines Agency. ARMOR3-SV has been initiated at more than 15 sites in the United States, with site initiations in Canada and the United Kingdom anticipated later in June. Additional study centers throughout North America, Western Europe and Australia are expected to join the study in the coming months. In addition, with recent finalization of the components of the AR-V7 clinical trial assay, technology transfer activities and training of the global central laboratories are underway, and screening of eligible patients for the splice variant is expected to begin in July. The company expects topline data from ARMOR3-SV to be available by the end of 2016.
Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM
Jun 18 15
Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Lee H. Kalowski, Chief Financial Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|